Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.

By Anushka Patel, S. Macmahon, J. Chalmers, B. Neal, M. Woodward, L. Billot, S. Harrap, N. Poulter, M. Marre, M. Cooper and 11 more. The Lancet, 2007

1,941 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, methodology): “The ADVANCE trial enrolled 11 140 subjects with diabetes, irrespective of blood pressure, and randomly allocated the subjects to perindopril and indapamide or matching placebo.(96) With a drop of 5.”
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, neutral): “In the ADVANCE BP study, lowering BP to a mean of 135/75 mmHg further reduced the risk of cardiovascular events and total mortality.(397) In diabetic patients, antihypertensive treatment should be initiated when the BP is ≥140/80 mmHg.”
Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker (2012, methodology): “PREDICTION MODEL The ADVANCE study was a randomised trial of the efficacy of blood pressure and glucose control on macrovascular and microvascular events among high-risk individuals with type 2 diabetes.(78) These data were subsequently used to develop a prediction model for the risk of developing m”
Guidelines for the Primary Prevention of Stroke (2011, neutral): “The ADVANCE Trial also determined whether a fixed combination of perindopril and indapamide or matching placebo in 11 140 patients with type 2 diabetes mellitus would decrease major macrovascular and microvascular events.(307) After 4.”